# Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

> **NCT04989803** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kite, A Gilead Company** · enrollment: 247 (estimated)

## Conditions studied

- Relapsed and/or Refractory B-cell Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** KITE-363
- **BIOLOGICAL:** KITE-753

## Key facts

- **NCT ID:** NCT04989803
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-27
- **Primary completion:** 2030-02
- **Final completion:** 2030-02
- **Target enrollment:** 247 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989803, "Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04989803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*